Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Ready to Sell Moderna? Check Out This Chart First
11:30am, Thursday, 10'th Nov 2022 The Motley Fool
Moderna shares are heading for a 35% decline this year.
5 Companies Buying Back Their Stock Aggressively in This Bear Market
11:12am, Thursday, 10'th Nov 2022 The Motley Fool
These companies clearly think their shares are good values.
2 Nasdaq 100 Stocks That Could Plunge as Much as 88%, According to Wall Street
10:21am, Thursday, 10'th Nov 2022 The Motley Fool
Select analysts believe these widely held growth stocks could plummet from their current price.
Ready to Sell Moderna? Check Out This Chart First
06:30am, Thursday, 10'th Nov 2022
Moderna shares are heading for a 35% decline this year.
Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update
05:35pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.
Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook
03:46pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.
Novavax stock rallies, even as company offers a dimmer sales forecast for vaccines
01:09pm, Wednesday, 09'th Nov 2022 MarketWatch
Shares of Novavax Inc. rallied after hours Tuesday, after the COVID-19 vaccine maker reported third-quarter results that were far better than expected.
5 Cheap Stocks Beginning Investors Can Buy Right Now
11:22am, Wednesday, 09'th Nov 2022 The Motley Fool
Investing in these five stocks could be a great way to start putting your money to work in the stock market.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
11:20am, Wednesday, 09'th Nov 2022 Zacks Investment Research
Smart Beta ETF report for FXH
Why Moderna Stock Could Still Be More Than 50% Overvalued
10:52am, Wednesday, 09'th Nov 2022 The Motley Fool
One valuation model could hint at a further decline for the vaccine stock.
Why Moderna Stock Could Still Be More Than 50% Overvalued
05:52am, Wednesday, 09'th Nov 2022
One valuation model could hint at a further decline for the vaccine stock.
8 Analysts Have This to Say About Moderna
09:50pm, Monday, 07'th Nov 2022 Benzinga
Analysts have provided the following ratings for Moderna (NASDAQ:MRNA) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
0
4
0
0
Last 30
Why Moderna Stock Jumped on Monday
09:47pm, Monday, 07'th Nov 2022 The Motley Fool
The market was pleased with the biotech's latest regulatory win.
Why Moderna Stock Jumped on Monday
04:47pm, Monday, 07'th Nov 2022
The market was pleased with the biotech's latest regulatory win.
The Big Pharma Giants Are Down
11:35am, Sunday, 06'th Nov 2022
It's evident that big pharma giant Moderna (NASDAQ: MRNA) is going through troubled times. Worse, it's dragging other big Pharma giants with it.
